20 Jun 2024
BEAT® Antibody Engineering Platform
Development of a 10 g/L process for a difficult-to-express multispecific antibody format using a holistic process development approach
Peltret M. et al.
Journal of Biotechnology
22 Apr 2024
BEAT® Antibody Engineering Platform
Alternative splicing for tuneable expression of protein subunits at desired ratios
Aebischer-Gumy C. et al.
mAbs
7 April 2024
ISB 2001
Oral Presentation: ISB 2001, a BCMA and CD38 dual targeting T-cell engager, demonstrates superior cytotoxicity relative to teclistamab in the samples of patients relapsing from CD38 and BCMA targeted immunotherapies
Perro, M. et al.
American Association for Cancer Research Annual Meeting
06 Mar 2024
ISB 1442
Development of ISB 1442, a CD38 and CD47bispecific biparatopic antibody innate cellmodulator for the treatment of multiplemyeloma
Grandclément C. et al.
Nature Communications
11 Dec 2023
ISB 1442
Poster: Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Kazandjian D. et al.
American Society of Hematology Annual Meeting
10 Dec 2023
ISB 1342
Poster: Dose Escalation of ISB 1342, a Novel CD38xCD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Kapoor P. et al.
American Society of Hematology Annual Meeting
10 Dec 2023
ISB 2001
Poster: A Phase 1, First-in-Human, Dose Escalation and Dose-Expansion Study of a BCMAxCD38xCD3 Targeting Trispecific Antibody ISB 2001 in Subjects with Relapsed/Refractory Multiple Myeloma (RRMM)
Sia H. et al.
American Society of Hematology Annual Meeting
5th Nov 2023
GRC 54276
Clinical Abstract: Phase 1 First In Human Study Evaluating The Safety, Tolerability, Pharmacokinetics And Efficacy Of Grc54276, A Novel HPK1 Thronine-Kinase Inhibitor, In Advanced Solid Tumours And Lymphomas.
Doddihal H. et. al.
European Hematology Association
22 May 2023
ISB 1342
Pre-clinical Characterization of ISB 1342, a CD38xCD3 T-cell Engager for Relapsed/Refractory Multiple Myeloma
Perro M. et al.
Blood
17 Apr 2023
ISB 2001
Overcoming Mechanisms of Escape from Treatments for Multiple Myeloma by ISB 2001, a first-in-Class Trispecific BCMA and CD38 targeted T Cell Engager
Perro M. et al.
American Association for Cancer Research Annual Meeting